CoChat

Exploiting Metabolic Vulnerabilities of Cancer with Precision and Accuracy

Open access
Wolpaw, Adam J., Dang, Chi V. · 2018 · Trends in Cell Biology
Cited by 146

The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.

Abstract

The links between oncogenic drivers and cancer cell metabolism have emerged over the past several decades, indicating that constitutive oncogenic growth signaling can render cancers susceptible to metabolic interventions. While significant progress has been achieved in identifying metabolic vulnerabilities of cancer cells, the complexity of the tumor microenvironment (TME) and the dynamic nature of organismal circadian metabolism challenge the precision of targeting cancer metabolism. Herein, current progress in the areas of cancer metabolism and TME metabolism is reviewed, highlighting how cancer metabolism can be accurately and precisely targeted.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.tcb.2017.11.006

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 43 references

Research works printed but not linked: 57

  1. Cantor, 2012, Cancer cell metabolism: one hallmark, many faces, Cancer Discov., 2, 881, 10.1158/2159-8290.CD-12-0345 · DOI · Paper page
  2. Buescher, 2015, A roadmap for interpreting 13C metabolite labeling patterns from cells, Curr. Opin. Biotechnol., 34, 189, 10.1016/j.copbio.2015.02.003 · DOI · Paper page
  3. Camarda, 2016, Inhibition of fatty acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer, Nat. Med., 22, 427, 10.1038/nm.4055 · DOI · Paper page
  4. Huang, 2016, Hepatocellular carcinoma redirects to ketolysis for progression under nutrition deprivation stress, Cell Res., 26, 1112, 10.1038/cr.2016.109 · DOI · Paper page
  5. Pandey, 2017, The see-saw of Keap1–Nrf2 pathway in cancer, Crit. Rev. Oncol. Hematol., 116, 89, 10.1016/j.critrevonc.2017.02.006 · DOI
  6. Jaramillo, 2013, The emerging role of the Nrf2–Keap1 signaling pathway in cancer, Genes Dev., 27, 2179, 10.1101/gad.225680.113 · DOI · Paper page
  7. Viswanathan, 2017, Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway, Nature, 547, 453, 10.1038/nature23007 · DOI · Paper page
  8. Mucaj, 2012, Effects of hypoxia and HIFs on cancer metabolism, Int. J. Hematol., 95, 464, 10.1007/s12185-012-1070-5 · DOI
  9. Danhier, 2017, Cancer metabolism in space and time: beyond the Warburg effect, Biochim. Biophys. Acta, 1858, 556, 10.1016/j.bbabio.2017.02.001 · DOI · Paper page
  10. Maley, 2017, Classifying the evolutionary and ecological features of neoplasms, Nat. Rev. Cancer, 17, 605, 10.1038/nrc.2017.69 · DOI · Paper page
  11. Strickaert, 2017, Cancer heterogeneity is not compatible with one unique cancer cell metabolic map, Oncogene, 36, 2637, 10.1038/onc.2016.411 · DOI
  12. Nieman, 2011, Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth, Nat. Med., 17, 1498, 10.1038/nm.2492 · DOI · Paper page
  13. Wong, 2017, Endothelial cell metabolism in health and disease: impact of hypoxia, EMBO J., 36, 2187, 10.15252/embj.201696150 · DOI · Paper page
  14. De Bock, 2013, Role of PFKFB3-driven glycolysis in vessel sprouting, Cell, 154, 651, 10.1016/j.cell.2013.06.037 · DOI · Paper page
  15. Lee, 2015, A lactate-induced response to hypoxia, Cell, 161, 595, 10.1016/j.cell.2015.03.011 · DOI · Paper page
  16. Murray, 2015, Snapshot: immunometabolism, Cell Metab., 22, 10.1016/j.cmet.2015.06.014 · DOI
  17. O’Neill, 2016, A guide to immunometabolism for immunologists, Nat. Rev. Immunol., 16, 553, 10.1038/nri.2016.70 · DOI · Paper page
  18. Buck, 2017, Metabolic instruction of immunity, Cell, 169, 570, 10.1016/j.cell.2017.04.004 · DOI · Paper page
  19. Farber, 1949, Some observations on the effect of folic acid antagonists on acute leukemia and other forms of incurable cancer, Blood, 4, 160, 10.1182/blood.V4.2.160.160 · DOI · Paper page
  20. Landau, 1958, Animal responses to 2-deoxy-D-glucose administration, Proc. Soc. Exp. Biol. Med., 99, 124, 10.3181/00379727-99-24268 · DOI · Paper page
  21. Landau, 1958, Certain metabolic and pharmacologic effects in cancer patients given infusions of 2-deoxy-D-glucose, J. Natl. Cancer Inst., 21, 485
  22. Doherty, 2014, Blocking lactate export by inhibiting the Myc target MCT1 disables glycolysis and glutathione synthesis, Cancer Res., 74, 908, 10.1158/0008-5472.CAN-13-2034 · DOI · Paper page
  23. Chan, 2011, Targeting GLUT1 and the Warburg effect in renal cell carcinoma by chemical synthetic lethality, Sci. Transl. Med., 3, 94ra70, 10.1126/scitranslmed.3002394 · DOI · Paper page
  24. Le, 2010, Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression, Proc. Natl. Acad. Sci. U. S. A., 107, 2037, 10.1073/pnas.0914433107 · DOI · Paper page
  25. Schulze, 2012, How cancer metabolism is tuned for proliferation and vulnerable to disruption, Nature, 491, 364, 10.1038/nature11706 · DOI · Paper page
  26. Tennant, 2010, Targeting metabolic transformation for cancer therapy, Nat. Rev. Cancer, 10, 267, 10.1038/nrc2817 · DOI · Paper page
  27. Galluzzi, 2013, Metabolic targets for cancer therapy, Nat. Rev. Drug Discov., 12, 829, 10.1038/nrd4145 · DOI · Paper page
  28. Vander Heiden, 2011, Targeting cancer metabolism: a therapeutic window opens, Nat. Rev. Drug Discov., 10, 671, 10.1038/nrd3504 · DOI · Paper page
  29. Jones, 2012, Targeting cancer metabolism – aiming at a tumour’s sweet-spot, Drug Discov. Today, 17, 232, 10.1016/j.drudis.2011.12.017 · DOI · Paper page
  30. Noble, 2017, Inhibition of monocarboxyate transporter 1 by AZD3965 as a novel therapeutic approach for diffuse large B-cell lymphoma and Burkitt lymphoma, Haematologica, 102, 1247, 10.3324/haematol.2016.163030 · DOI · Paper page
  31. Doherty, 2013, Targeting lactate metabolism for cancer therapeutics, J. Clin. Invest., 123, 3685, 10.1172/JCI69741 · DOI · Paper page
  32. Marchiq, 2015, Genetic disruption of lactate/H+ symporters (MCTs) and their subunit CD147/BASIGIN sensitizes glycolytic tumor cells to phenformin, Cancer Res., 75, 171, 10.1158/0008-5472.CAN-14-2260 · DOI · Paper page
  33. Chen, 2016, Identification of a potent inhibitor targeting human lactate dehydrogenase A and its metabolic modulation for cancer cell line, Bioorg. Med. Chem. Lett., 26, 72, 10.1016/j.bmcl.2015.11.025 · DOI
  34. Ganapathy-Kanniappan, 2013, Anticancer efficacy of the metabolic blocker 3-bromopyruvate: specific molecular targeting, Anticancer Res., 33, 13
  35. Birsoy, 2013, MCT1-mediated transport of a toxic molecule is an effective strategy for targeting glycolytic tumors, Nat. Genet., 45, 104, 10.1038/ng.2471 · DOI · Paper page
  36. Cantor, 2017, Physiologic medium rewires cellular metabolism and reveals uric acid as an endogenous inhibitor of UMP synthase, Cell, 169, 258, 10.1016/j.cell.2017.03.023 · DOI · Paper page
  37. Tanaka, 2015, Compensatory glutamine metabolism promotes glioblastoma resistance to mTOR inhibitor treatment, J. Clin. Invest., 125, 1591, 10.1172/JCI78239 · DOI · Paper page
  38. Lampa, 2017, Glutaminase is essential for the growth of triple-negative breast cancer cells with a deregulated glutamine metabolism pathway and its suppression synergizes with mTOR inhibition, PLoS One, 12, 10.1371/journal.pone.0185092 · DOI · Paper page
  39. Yuan, 2013, Phenformin enhances the therapeutic benefit of BRAFV600E inhibition in melanoma, Proc. Natl. Acad. Sci. U. S. A., 110, 18226, 10.1073/pnas.1317577110 · DOI · Paper page
  40. Kim, 2017, Phenformin inhibits myeloid-derived suppressor cells and enhances the anti-tumor activity of PD-1 blockade in melanoma, J. Invest. Dermatol., 137, 1740, 10.1016/j.jid.2017.03.033 · DOI
  41. O’Neill, 2016, Immunometabolism governs dendritic cell and macrophage function, J. Exp. Med., 213, 15, 10.1084/jem.20151570 · DOI · Paper page
  42. He, 2017, CD155T/TIGIT signaling regulates CD8+ T cell metabolism and promotes tumor progression in human gastric cancer, Cancer Res., 77, 6375, 10.1158/0008-5472.CAN-17-0381 · DOI · Paper page
  43. Gentles, 2015, The prognostic landscape of genes and infiltrating immune cells across human cancers, Nat. Med., 21, 938, 10.1038/nm.3909 · DOI · Paper page
  44. Weger, 2017, Stem cells and the circadian clock, Dev. Biol., 431, 111, 10.1016/j.ydbio.2017.09.012 · DOI
  45. Bass, 2016, Circadian time signatures of fitness and disease, Science, 354, 994, 10.1126/science.aah4965 · DOI · Paper page
  46. Altman, 2017, Correspondence: Oncogenic MYC persistently upregulates the molecular clock component REV-ERBα, Nat. Commun., 8, 10.1038/ncomms14862 · DOI
  47. Altman, 2015, MYC disrupts the circadian clock and metabolism in cancer cells, Cell Metab., 22, 1009, 10.1016/j.cmet.2015.09.003 · DOI · Paper page
  48. Levi, 1997, Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. International Organization for Cancer Chronotherapy, Lancet, 350, 681, 10.1016/S0140-6736(97)03358-8 · DOI · Paper page
  49. Innominato, 2014, The circadian timing system in clinical oncology, Ann. Med., 46, 191, 10.3109/07853890.2014.916990 · DOI · Paper page
  50. Ballesta, 2017, Systems chronotherapeutics, Pharmacol. Rev., 69, 161, 10.1124/pr.116.013441 · DOI · Paper page
  51. Lin, 2016, Discovery of a novel 2,6-disubstituted glucosamine series of potent and selective hexokinase 2 inhibitors, ACS Med. Chem. Lett., 7, 217, 10.1021/acsmedchemlett.5b00214 · DOI
  52. Cui, 2016, Discovery of 2-((3-cyanopyridin-2-yl)thio)acetamides as human lactate dehydrogenase A inhibitors to reduce the growth of MG-63 osteosarcoma cells: virtual screening and biological validation, Bioorg. Med. Chem. Lett., 26, 3984, 10.1016/j.bmcl.2016.06.083 · DOI
  53. Billiard, 2013, Quinoline 3-sulfonamides inhibit lactate dehydrogenase A and reverse aerobic glycolysis in cancer cells, Cancer Metab., 1, 19, 10.1186/2049-3002-1-19 · DOI · Paper page
  54. Rai, 2017, Discovery and optimization of potent, cell-active pyrazole-based inhibitors of lactate dehydrogenase (LDH), J. Med. Chem., 10.1021/acs.jmedchem.7b00941 · DOI · Paper page
  55. Ward, 2012, Design and synthesis of novel lactate dehydrogenase A inhibitors by fragment-based lead generation, J. Med. Chem., 55, 3285, 10.1021/jm201734r · DOI · Paper page
  56. Alistar, 2017, Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, Phase 1 trial, Lancet Oncol., 18, 770, 10.1016/S1470-2045(17)30314-5 · DOI · Paper page
  57. Bose, 2017, Treatment of relapsed/refractory acute myeloid leukemia, Curr. Treat. Options Oncol., 18, 17, 10.1007/s11864-017-0456-2 · DOI · Paper page

Cited by

Metadata

Authors
Wolpaw, A. J., & Dang, C. V.
Venue
Trends in Cell Biology
Publisher
Elsevier BV
Published
2018-03
Volume
28
Issue
3
Pages
201-212
ISSN
0962-8924 (ISSN-L)
OpenAlex
W2774281839
Cited by
146
References
43
FWCI
1.27
Type
journal article
Language
en
Open access
green
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Funders
  • NCI (CA051497, CA057341)
  • Ludwig Institute for Cancer Research
  • Children’s Hospital of Philadelphia Department of Pediatrics training (5T32GM00736)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.